

**Pioneering innovative
therapies for patients with
life-threatening diseases**

Celyad SA
General Assembly
May 5, 2020



Celyad



Agenda

- Introduction *by Filippo Petti*
- Legal formalities *by Philippe Dechamps*
- Business Update, *by Filippo Petti*
- Q&A, *by Filippo Petti*
- Results of the votes, *by Philippe Dechamps*
- Conclusion, *by Philippe Dechamps*



Filippo Petti
Chief Executive Officer



Philippe Dechamps
Chief Legal Officer




Introduction by Filippo Petti



Legal Formalities by Philippe Dechamps



2019 – A Year in Review



Continued Progression Towards a Diversified Pipeline of CAR-T Therapies

| | Product | Target | Study | Design | Preclinical | IND Submission | Phase 1 |
|------------|----------------------|--------|------------|--------------------------------|---------------------|----------------|---------|
| Autologous | CYAD-01 | NKG2DL | THINK | Standalone w/o Preconditioning | r/r AML / MDS | | |
| | | | DEPLETHINK | Preconditioning with CyFlu | r/r AML / MDS | | |
| | CYAD-02 | NKG2DL | CYCLE-1 | Preconditioning with CyFlu | r/r AML / MDS | | |
| Allogeneic | TIM Technology | | alloSHRINK | Concurrent with FOLFOX | mCRC | | |
| | CYAD-101 | NKG2DL | | | Solid Tumors | | |
| | CYAD-103 | NKG2DL | | | | | |
| | shRNA Platform | | | | Multiple myeloma | | |
| | CYAD-211 | BCMA | | | B-cell malignancies | | |
| | CYAD-221 | CD19 | | | | | |
| CYAD-231 | NKG2DL x Undisclosed | | | | | | |

Treasury Position, SOx Compliance and Upcoming Financial Calendar

- As of year-end December 31, 2019, total cash, cash equivalents and short-term investments totaled €39.3 million (\$44.0 million)
 - Treasury position expected to support the company's activities through the first half of 2021
- Sarbanes-Oxley (SOx) Act of 2002 – Company recently confirmed that it will need to be compliant with the SOx Act of 2002 by year-end 2020 ⁽¹⁾
 - As such, an additional fee of €50,000 HTVA to Ernst & Young (EY) associated for services related to SOx compliance will need to be approved at a future shareholders' meeting
- Upcoming Financial Calendar
 - May 7th – First Quarter Business Update
 - August 6th – Half Year Results
 - November 10th – Third Quarter Business Update

(1) Securities and Exchange Commission (SEC) rule with effect as from April 27, 2020.

Milestones

First Half 2020

- ✓ *CYAD-01 in r/r AML and MDS:* Begin expansion segment of Phase 1 THINK trial evaluating CYAD-01 without preconditioning chemotherapy
- ✓ *CYAD-02 in r/r AML and MDS:* Enroll first patient in Phase 1 dose-escalation CYCLE-1 trial evaluating CYAD-02 with CyFlu preconditioning

Second Quarter 2020

- CYAD-101 in mCRC:* Data from three additional patients from alloSHRINK trial at ASCO Virtual Scientific Program (May 29 -31)
- CYAD-211 in multiple myeloma:* Submission of IND application for shRNA-based allogeneic BCMA CAR-T therapy

Second Half 2020

- CYAD-101 in mCRC:* Begin expansion cohort of alloSHRINK trial
- CYAD-01 in r/r AML and MDS:* Report preliminary data from expansion segment of Phase 1 THINK and DEPLETHINK trials
- CYAD-02 in r/r AML and MDS:* Report preliminary data from dose-escalation Phase 1 CYCLE-1 trial





Results of the votes

